Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK5533524 · 1 trial · 1 indication
ORR is defined as the proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1).
| Arm | Type | Description |
|---|---|---|
| Part 1a: GSK5533524 Dose Escalation | EXPERIMENTAL | - |
| Part 1b: GSK5533524 Dose Expansion | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GSK5533524 | DRUG | GSK5533524 will be administered. |
Inclusion Criteria: * Is at least 18 years of age or the legal age of consent * Has histologically or cytologically confirmed advanced/metastatic solid tumor that is refractory or intolerant to standard therapy, has exhausted all treatment options and is not considered a candidate for definitive ra...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
GSK5533524 is an investigational small molecule developed by GSK plc for the treatment of advanced solid tumors. It is being studied in a first-time-in-human Phase 1 clinical trial in adult participants with neoplasms. GSK5533524 has not been approved by any regulatory authority and remains in clinical development.
GSK5533524 is being evaluated for the treatment of advanced solid tumors, also described as neoplasms, in adult patients. The Phase 1 study enrolls participants aged 18 years and older with advanced solid tumors. Its use remains investigational, and no approved indication currently exists for this drug.
GSK5533524 is developed by GSK plc, which trades under the ticker GSK. The company is running the first-time-in-human study of the small molecule in adult participants with advanced solid tumors across sites in the United States, Canada, Denmark, Finland, France, Japan, Spain, and the United Kingdom.
GSK5533524 is in Phase 1 clinical development. It is being tested in a first-time-in-human study designed to investigate safety and preliminary activity in adult participants with advanced solid tumors. The drug is investigational and has not received FDA approval.
GSK5533524 is being studied in one active clinical trial, NCT07438782, titled a first-time-in-human study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors. The trial is currently recruiting and plans to enroll 97 participants.
The Phase 1 trial NCT07438782 is a controlled, non-randomized, open-label study of GSK5533524 given alone or in combination in adults with advanced solid tumors. It plans to enroll 97 participants aged 18 years and older, including all sexes, and is recruiting across eight countries.